FIG. 2.

PKM2 is oxidized by C26:0 excess in human fibroblasts. (A) Redox proteomics experiments were performed in human control and X-ALD fibroblasts (n=5 per genotype and condition), which were treated for 7 days with BSA-conjugated C26:0 (100 μM) or BSA as control in a serum-free medium. Western blot with an antibody anti-DNP was performed to identify oxidized proteins. Western blot was performed with a specific antibody against pyruvate kinase (PKM2) to validate the protein identification obtained by MS (B) or to quantify their expression (C). Relative protein level is expressed as a percentage of control, and referred to γ-tubulin as loading marker. Significant differences were revealed by ANOVA followed by Tukey HSD post hoc test.